Who: Dr Reddy’s Laboratories
What: Signed pact with PanTheryx
When: 9 September 2015
Dr Reddy’s Laboratories on 9 September 2015 signed pact with US-based medical company PanTheryx to market PanTheryx’s nutritional intervention DiaResQ for infectious diarrhea in India, Nepal, Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets.
Dr Reddy’s will market the DiaResQ product in India and Nepal under the Reliqua brand. With this addition of Reliqua to its existing portfolio of gastrointestinal brands, Dr Reddy’s can now provide an important new tool for healthcare practitioners across the many markets it serves.
• DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function.
• The product was recently recognised in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
About Infectious diarrhea
Infectious diarrhea is a major world health challenge and globally approximately 1.7 billion cases of Infectious diarrhea occur annually in children under five. Almost 760000 of these children under five die every year as a result of this condition. And, the Pediatric infectious diarrhea even kills the deceased.
• Founded in 2007, PanTheryx is a global medical nutrition company based in Boulder, Colorado USA, and is dedicated to improving global health and quality of life through innovative life science.
• PanTheryx is focused on the research, development and commercialization of medical nutrition products targeting the gastrointestinal microbiome.